+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06365671

Study of CD19 CAR-T Treatment After Autologous Stem Cell Transplant for Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma With High-Risk Features

Led by Ruijin Hospital · Updated on 2026-01-06

16

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of CD19 CAR-T cell therapy after high-dose chemotherapy and autologous stem-cell transplantation ASCT in patients with relapsed or refractory B-cell Non-Hodgkins Lymphoma B-NHL who have high-risk factors such as extranodal involvement, bulky tumors, or TP53 gene alterations. This single-arm, open-label clinical trial aims to understand treatment outcomes including response rates and side effects. Participants will receive high-dose chemotherapy followed by an infusion of their own stem cells to restore bone marrow function. Then, on about day 3 after transplantation, they will receive a fixed dose of 100 million CD19 CAR-T cells. This combination approach is being studied to determine its impact on disease control and patient safety. During the study, participants will be closely monitored with assessments to measure the best complete response rate at 3 months after CAR-T infusion, as well as other outcomes like overall survival and progression-free survival over 2 years. Researchers will also track side effects such as cytokine release syndrome, neurotoxicity, and other treatment-related toxicities. The total study duration includes at least two years of follow-up to evaluate long-term effects and safety.

CONDITIONS

Brief Title

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

Research Team

W

Weili Zhao

L

Li Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here